IMB Dx Company Description

IMB Dx, Inc. provides liquid biopsy platform in South Korea.

It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test.

The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection.

IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.

IMB Dx, Inc.

Country	South Korea
Founded	2018
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: BYC Highcity Bldg A Seoul, 08506 South Korea
Phone	82 2 6951 2906
Website	imbdx.com

Stock Details

Ticker Symbol	461030
Exchange	Korea Exchange - KOSDAQ
Reporting Currency	KRW
SIC Code	2836